Innoviva price target raised to $42 from $35 at BTIG

BTIG raised the firm’s price target on Innoviva (INVA) to $42 from $35 and keeps a Buy rating on the shares after its Q1 results. Royalty revenue from Breo and Anoro was $58.6M, continuing to show resilience as a backbone to the business, the analyst tells investors in a research note.